{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Means and standard deviations of Plasma Inhibitory Activity (PIA) will be given by genotype","groups":[{"description":"Population Description: Eligible patients with MLL-G (germline, or non-rearranged)\n\nAsparaginase: Given IV, IM, or PO\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IV or IT\n\nDaunorubicin Hydrochloride: Given IV\n\nDexamethasone: Given IV or PO\n\nEtoposide: Given IV\n\nFilgrastim: Given IV or SC\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeucovorin Calcium: Given IV\n\nMercaptopurine: Given PO\n\nMethotrexate: Given IV, IT, or PO\n\nMethylprednisolone: Given IV\n\nPegaspargase: Given IM\n\nPharmacological Study: Correlative studies\n\nPrednisone: Given PO\n\nTherapeutic Hydrocortisone: Given IT\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Arm A (Standard Risk MLL-G)"},{"description":"Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age \\>= 90 days at diagnosis and High Risk (HR) if age \\< 90 days at diagnosis.\n\nAsparaginase: Given IV, IM, or PO\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IV or IT\n\nDaunorubicin Hydrochloride: Given IV\n\nDexamethasone: Given IV or PO\n\nEtoposide: Given IV\n\nFilgrastim: Given IV or SC\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeucovorin Calcium: Given IV\n\nMercaptopurine: Given PO\n\nMethotrexate: Given IV, IT, or PO\n\nMethylprednisolone: Given IV\n\nPegaspargase: Given IM\n\nPharmacological Study: Correlative studies\n\nPrednisone: Given PO\n\nTherapeutic Hydrocortisone: Given IT\n\nVincristine Sulfate: Given IV","id":"OG001","title":"Arm B (IR/HR MLL-R Chemotherapy)"},{"description":"Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age \\>= 90 days at diagnosis and High Risk (HR) if age \\< 90 days at diagnosis.\n\nAsparaginase: Given IV, IM, or PO\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IV or IT\n\nDaunorubicin Hydrochloride: Given IV\n\nDexamethasone: Given IV or PO\n\nEtoposide: Given IV\n\nFilgrastim: Given IV or SC\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLestaurtinib: Given PO\n\nLeucovorin Calcium: Given IV\n\nMercaptopurine: Given PO\n\nMethotrexate: Given IV, IT, or PO\n\nMethylprednisolone: Given IV\n\nPegaspargase: Given IM\n\nPharmacological Study: Correlative studies\n\nPrednisone: Given PO\n\nTherapeutic Hydrocortisone: Given IT\n\nVincristine Sulfate: Given IV","id":"OG002","title":"Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)"}],"populationDescription":"Data was and never will be collected","reportingStatus":"POSTED","timeFrame":"At 3 years","title":"Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With PIA Values","type":"SECONDARY"}